<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>22841467</identifier>
<setSpec>1578-8989</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Aguilar, Eva</dc:author>
<dc:author>Coronas, Ramón</dc:author>
<dc:author>Caixàs, Assumpta</dc:author>
<dc:description xml:lang="en">Patients with schizophrenia have a shorter life expectancy and their risk of dying from a cardiovascular disease is higher than the general population. Both facts have been attributed to the raised presence of metabolic syndrome. There is a big amount of scientific publications that deals with the relationship between schizophrenia, antipsychotic treatment, and the development of metabolic syndrome. There is also information about recommendations and clinical guides to achieve an adequate prevention, screening, and treatment of the disease. The aim of this review is to update the current information about this issue and to understand related etiologic factors, differences between antipsychotic drugs, and the current recommendations for patient's care.</dc:description>
<dc:type>Journal Article</dc:type>
<dc:language>es</dc:language>
<dc:date>2012 Nov 17 </dc:date>
<dc:title xml:lang="es">Síndrome metabólico en pacientes esquizofrénicos con tratamiento antipsicótico.</dc:title>
<dc:title xml:lang="en">[Metabolic syndrome in patients with schizophrenia and antipsychotic treatment].</dc:title>
<dc:publisher>Medicina clinica</dc:publisher>
</metadata>
</record>
</pubmed-document>
